We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00119691
Recruitment Status : Completed
First Posted : July 14, 2005
Last Update Posted : September 12, 2013
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.

Condition or disease Intervention/treatment Phase
Congestive Heart Failure Renal Insufficiency Drug: Nesiritide Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction
Study Start Date : April 2003
Primary Completion Date : November 2005
Study Completion Date : November 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
Drug Information available for: Nesiritide
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Nesiritide + standard of care
Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
Drug: Nesiritide
Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
Other Name: Natrecor
Active Comparator: Standard of care
Standard of care until adequate diuresis achieved
Drug: Nesiritide
Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
Other Name: Natrecor


Outcome Measures

Primary Outcome Measures :
  1. Renal function [ Time Frame: within 7 days after randomization ]

Secondary Outcome Measures :
  1. Weight loss [ Time Frame: Within 7 days from randomization ]
  2. Days to optimal volume status [ Time Frame: From randomization till day 7 or sooner ]
  3. Concomitant diuretic use [ Time Frame: Within 7 days from randomization ]
  4. Global symptom assessment [ Time Frame: 24 hrs and 3 days after randomization ]
  5. Length of stay [ Time Frame: From admission to discharge or day 7 ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Decompensated heart failure hospitalization with at least 1 symptom and 1 sign of elevated filling pressures
  • Admission estimated creatinine clearance =< 50 cc/min.

Exclusion Criteria:

  • Systolic blood pressure < 85 mm Hg
  • Cardiogenic shock
  • Volume depletion
  • Myocardial infarction, unstable angina within last 30 days
  • Significant valvular stenosis, hypertrophic/restrictive cardiomyopathy, or constrictive pericarditis
  • Chronic hemodialysis
  • Anticipated major procedure during hospitalization i.e. left heart catheterization, surgery, or transplantation
  • Enrolled in another research protocol within last 30 days.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00119691


Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Scios, Inc.
Investigators
Principal Investigator: Anju Nohria, MD Brigham and Women's Hospital
More Information

Responsible Party: Anju Nohria, Associate Physician/Assistant Professor, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT00119691     History of Changes
Other Study ID Numbers: 2003-P00235
First Posted: July 14, 2005    Key Record Dates
Last Update Posted: September 12, 2013
Last Verified: September 2013

Additional relevant MeSH terms:
Heart Failure
Renal Insufficiency
Heart Diseases
Cardiovascular Diseases
Kidney Diseases
Urologic Diseases
Natriuretic Peptide, Brain
Natriuretic Agents
Physiological Effects of Drugs